D
D Agnusdei
Researcher at Eli Lilly and Company
Publications - 25
Citations - 1970
D Agnusdei is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Osteoporosis & Raloxifene. The author has an hindex of 18, co-authored 25 publications receiving 1816 citations.
Papers
More filters
Journal ArticleDOI
Quality of Life in Patients with Vertebral Fractures: Validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO)
Paul Lips,Cyrus Cooper,D Agnusdei,F Caulin,P. Egger,Olof Johnell,J. A. Kanis,S. Kellingray,Alain Leplège,Uri A. Liberman,Eugene V. McCloskey,Helmut W. Minne,J. Reeve,Jean-Yves Reginster,M. Scholz,Chris Todd,M.C. de Vernejoul,Ingela Wiklund +17 more
TL;DR: The QUALEFFO questionnaire as discussed by the authors was validated in a multicenter study in seven countries and the results confirmed the decreased quality of life in patients with vertebral fractures and showed that all five domains within each questionnaire discriminated significantly between fracture cases and controls.
Journal ArticleDOI
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis
Sarath Lekamwasam,Jonathan D. Adachi,D Agnusdei,J. P. Bilezikian,Steven Boonen,F. Borgström,Cyrus Cooper,A. Diez Perez,R. Eastell,Lorenz C. Hofbauer,John A. Kanis,Bente L. Langdahl,Olga Lesnyak,Roman S. Lorenc,Eugene V. McCloskey,Osvaldo D. Messina,Nicola Napoli,Barbara Obermayer-Pietsch,Stuart H. Ralston,P. N. Sambrook,S Silverman,Manuel Sosa,Jan J. Stepan,G. Suppan,D. A. Wahl,J E Compston +25 more
TL;DR: Guidance for glucocorticoid-induced osteoporosis is updated in the light of new treatments and methods of assessment, and national guidelines derived from this resource need to be tailored within the national healthcare framework of each country.
Journal ArticleDOI
Treatment Failure in Osteoporosis
Adolfo Diez-Perez,Jonathan D. Adachi,D Agnusdei,J. P. Bilezikian,Juliet E. Compston,Steve Cummings,R. Eastell,Erik Fink Eriksen,Jesús González-Macías,Uri A. Liberman,D. A. Wahl,Ego Seeman,John A. Kanis,Cyrus Cooper,Cyrus Cooper +14 more
TL;DR: The provision of pragmatic criteria to define failure to respond to treatment provides an unmet clinical need and may stimulate research into an important issue.
Journal ArticleDOI
The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro.
Anna Taranta,Marina Brama,Marina Brama,Anna Teti,V. De Luca,V. De Luca,Roberto Scandurra,Giovanni Spera,D Agnusdei,J.D Termine,Silvia Migliaccio,Silvia Migliaccio +11 more
TL;DR: Data show that raloxifene negatively modulates osteoclasts, and positively affects osteoblasts, suggesting not only an antiresorptive role, but also an osteoblast stimulatory role.
Journal ArticleDOI
Quality of life as outcome in the treatment of osteoporosis: The development of a questionnaire for quality of life by the European foundation for osteoporosis
Paul Lips,Cyrus Cooper,D Agnusdei,F Caulin,P. Egger,Olof Johnell,J. A. Kanis,Uri A. Liberman,Helmut W. Minne,J. Reeve,Jean-Yves Reginster,M.C. de Vernejoul,Ingela Wiklund +12 more
TL;DR: Preliminary results indicate that the reproducibility is sufficient and that the questionnaire is able to discriminate between patients with vertebral osteoporosis and control subjects.